| 1 | Ranibizumab versus verteporfin for neovascular age-related macular degeneration. (Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S, ANCHOR Study Group) N Engl J Med 2006 Oct 05;355(14):1432-44 3397 Citations |
| 1 | Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. (Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR, MARINA Study Group) Ophthalmology 2007 Feb;114(2):246-52 387 Citations |
| 1 | Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. (Kaiser PK, Blodi BA, Shapiro H, Acharya NR, MARINA Study Group) Ophthalmology 2007 Oct;114(10):1868-75 207 Citations |
| 1 | Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. (Chang TS, Bressler NM, Fine JT, Dolan CM, Ward J, Klesert TR, MARINA Study Group) Arch Ophthalmol 2007 Nov;125(11):1460-9 212 Citations |
| 1 | Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. (Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T, ANCHOR Study Group) Ophthalmology 2009 Jan;116(1):57-65.e5 1280 Citations |
| 1 | Improved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. (Bressler NM, Chang TS, Fine JT, Dolan CM, Ward J, Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age-Related Macular Degeneration (ANCHOR) Research Group) Arch Ophthalmol 2009 Jan;127(1):13-21 87 Citations |
| 1 | Ranibizumab for coloboma-related choroidal neovascular membrane in a child. (Goodwin P, Shields CL, Ramasubramanian A, Brown GC, Shields JA) J AAPOS 2009 Dec;13(6):616-7 18 Citations |
| 1 | Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. (Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, Ferris FL 3rd, Friedman SM, Glassman AR, Miller KM, Scott IU, Stockdale CR, Sun JK) Ophthalmology 2010 Jun;117(6):1064-1077.e35 1321 Citations |
| 1 | Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. (Busbee BG, Ho AC, Brown DM, Heier JS, Suñer IJ, Li Z, Rubio RG, Lai P, HARBOR Study Group) Ophthalmology 2013 May;120(5):1046-56 486 Citations |
| 1 | Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy. (Diabetic Retinopathy Clinical Research Network*) JAMA Ophthalmol 2013 Mar;131(3):283-93 95 Citations |
| 1 | Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. (Weinberg DV, Shapiro H, Ehrlich JS) Ophthalmology 2013 Jun;120(6):1278-82 14 Citations |
| 1 | Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial. (Bressler SB, Qin H, Melia M, Bressler NM, Beck RW, Chan CK, Grover S, Miller DG, Diabetic Retinopathy Clinical Research Network) JAMA Ophthalmol 2013 Aug;131(8):1033-40 106 Citations |
| 1 | Comparison of intravitreal ranibizumab and bevacizumab for the treatment of macular edema secondary to retinal vein occlusion. (Yuan A, Ahmad BU, Xu D, Singh RP, Kaiser PK, Martin DF, Sears JE, Schachat AP, Ehlers JP) Int J Ophthalmol 2014;7(1):86-91 20 Citations |
| 1 | Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. (Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, Arnold-Bush B, Baker CW, Bressler NM, Browning DJ, Elman MJ, Ferris FL, Friedman SM, Melia M, Pieramici DJ, Sun JK, Beck RW) N Engl J Med 2015 Mar 26;372(13):1193-203 1441 Citations |
| 1 | Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment. (Bressler SB, Almukhtar T, Bhorade A, Bressler NM, Glassman AR, Huang SS, Jampol LM, Kim JE, Melia M, Diabetic Retinopathy Clinical Research Network Investigators) JAMA Ophthalmol 2015 May;133(5):589-97 75 Citations |
| 1 | Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema. (Wells JA, Glassman AR, Jampol LM, Aiello LP, Antoszyk AN, Baker CW, Bressler NM, Browning DJ, Connor CG, Elman MJ, Ferris FL, Friedman SM, Melia M, Pieramici DJ, Sun JK, Beck RW, Diabetic Retinopathy Clinical Research Network) JAMA Ophthalmol 2016 Feb;134(2):127-34 67 Citations |
| 1 | Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. (Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, Brucker AJ, Ferris FL, Hampton GR, Jhaveri C, Melia M, Beck RW, Diabetic Retinopathy Clinical Research Network) Ophthalmology 2016 Jun;123(6):1351-9 888 Citations |
| 1 | PANRETINAL PHOTOCOAGULATION VERSUS RANIBIZUMAB FOR PROLIFERATIVE DIABETIC RETINOPATHY: Comparison of Peripapillary Retinal Nerve Fiber Layer Thickness in a Randomized Clinical Trial. (Jampol LM, Odia I, Glassman AR, Baker CW, Bhorade AM, Han DP, Jaffe GJ, Melia M, Bressler NM, Tanna AP, Diabetic Retinopathy Clinical Research Network) Retina 2019 Jan;39(1):69-78 13 Citations |
| 1 | Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial. (Gross JG, Glassman AR, Liu D, Sun JK, Antoszyk AN, Baker CW, Bressler NM, Elman MJ, Ferris FL 3rd, Gardner TW, Jampol LM, Martin DF, Melia M, Stockdale CR, Beck RW, Diabetic Retinopathy Clinical Research Network) JAMA Ophthalmol 2018 Oct 01;136(10):1138-1148 371 Citations |
| 1 | Visual Field Changes Over 5 Years in Patients Treated With Panretinal Photocoagulation or Ranibizumab for Proliferative Diabetic Retinopathy. (Maguire MG, Liu D, Glassman AR, Jampol LM, Johnson CA, Baker CW, Bressler NM, Gardner TW, Pieramici D, Stockdale CR, Sun JK, DRCR Retina Network) JAMA Ophthalmol 2020 Mar 01;138(3):285-293 52 Citations |
| 1 | Long-term full-field and multifocal electroretinographic changes after treatment with ranibizumab in patients with diabetic macular edema. (Yigit K, Inan ÜÜ, Inan S, Dogan M, Yavas GF, Cetinkaya E) Int Ophthalmol 2021 Apr;41(4):1487-1501 6 Citations |
| 1 | Lapses in Care Among Patients Assigned to Ranibizumab for Proliferative Diabetic Retinopathy: A Post Hoc Analysis of a Randomized Clinical Trial. (Maguire MG, Liu D, Bressler SB, Friedman SM, Melia M, Stockdale CR, Glassman AR, Sun JK, DRCR Retina Network) JAMA Ophthalmol 2021 Dec 01;139(12):1266-1273 24 Citations |
